Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006562 · ClinicalTrials.gov registry record · Phase 4
PREvention of VENous ThromboEmbolism Following Radical Prostatectomy
A Phase 4 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 501
- Enrollment target
NCT03006562: Clinical Trial Phase 4 study, sponsored by Johns Hopkins University.
NCT03006562 is a Phase 4 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 501 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006562, a Phase 4 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 501 participants
- Enrollment target
Study Summary
The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).
Interventions
- DRUG Subcutaneous Heparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 501 participants |
| Start Date | 2017-07-01 |
| Est. Completion | 2019-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03006562
The ClinicalTrials.gov registry entry for NCT03006562 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 501 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Subcutaneous Heparin is the first listed.
NCT03006562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03006562 about?
NCT03006562 is a clinical study titled "PREvention of VENous ThromboEmbolism Following Radical Prostatectomy". The PREVENTER Trial aims to compare the use of perioperative pharmacologic prophylaxis (subcutaneous heparin) with intermittent pneumatic compression devices (IPCs) to the use of IPCs alone for the prevention of venous thromboembolism (VTE) after radical prostatectomy (RP).
What is the current status of trial NCT03006562?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 501 participants. The study started on 2017-07-01. Estimated completion is 2019-11-01.
What interventions are being tested in trial NCT03006562?
The interventions under investigation include: Subcutaneous Heparin (DRUG).
Who is sponsoring clinical trial NCT03006562?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.